Reference
- Dean BV, Stellpflug SJ, Burnett AM, Engebretsen KM. 2C or not 2C: phenethylamine designer drug review. J Med Toxicol 2013; 9:172–178.
- Lawn W, Barratt M, Williams M, Horne A, Winstock A. The NBOMe hallucinogenic drug series: Patterns of use, characteristics of users and self-reported effects in a large international sample. J Psychopharmacol 2014; 28:780–8.
- Wood DM, Sedefov R, Cunningham A, Dargan PI. Prevalence of use and acute toxicity associated with the use of NBOMe drugs. Clin Toxicol 2015; 53:85–92.
- Braden MR, Parrish JC, Naylor JC, Nichols DE. Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists. Mol Pharmacol 2006; 70:1956–1964.
- Bronstein AC, Spyker DA, Cantilena LR, Green JL, Rumack BH, Giffin SL. 2008 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 26th Annual Report. Clin Toxicol 2009; 47:911–1084.
- Forrester MB. 2C series phenethylamine derivative exposures in Texas. Subst Abuse 2013; 34:81–82.
- Forrester MB. NBOMe designer drug exposures reported to Texas poison centers. J Addict Dis 2014; 33:196–201.
- Yin S, Ho M. Monitoring a toxicological outbreak using Internet search query data. Clin Toxicol 2012; 50:818–822.
- Hanson CL, Cannon B, Burton S, Giraud-Carrier C. An exploration of social circles and prescription drug abuse through Twitter. J Med Internet Res 2013; 15:e189.
- Halberstadt AL, Geyer MA. Effects of the hallucinogen 2,5-dimethoxy-4-iodophenethylamine (2C-I) and superpotent N-benzyl derivatives on the head twitch response. Neuropharmacology 2014; 77:200–7.